Patents by Inventor He Xu

He Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170288394
    Abstract: A system, a switch assembly and an associated method. The system includes a number of switch assemblies, each including a switch module, isolation circuits, a detection unit, and a drive unit. The switch module includes power switch devices connected in parallel. The switch modules are connected in series. The isolation circuits each are connected in series to a gate terminal of at least one corresponding power switch device of the power switch devices. Each isolation circuit includes a capacitor or a controllable switch. The detection unit detects faults in at least one of the power switch devices. The drive unit is coupled to the switch module via the isolation circuits for driving the power switch devices of the corresponding switch module, and when the fault is detected, the drive unit is for turning on the power switch devices parallel connected to the at least one of faulty power switch devices.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Zhihui YUAN, He XU, Jie SHEN, Fan ZHANG, Stefan SCHROEDER
  • Patent number: 9751854
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 5, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, Tzu-Tshin Wong, He Xu, Tianlin Xu, Yingchun Ye
  • Patent number: 9745551
    Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem eel! derived mesenchymal-like stem/siromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: August 29, 2017
    Assignee: IMSTEM BIOTECHNOLOGY, INC.
    Inventors: Xiaofang Wang, Ren-He Xu
  • Patent number: 9725698
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: August 8, 2017
    Assignees: IMSTEM BIOTECHNOLOGY, INC., UNIVERSITY OF CONNECTICUT
    Inventors: Xiaofang Wang, Ren-He Xu
  • Publication number: 20170216290
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. DUFFEY, Dylan England, Brian Scott Freeze, Zhigen Hu, Steven Langston, Charles Mclntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Patent number: 9695154
    Abstract: Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra?, Rc, Rf, X2, Rd, Rd?, Re, Re?, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: July 4, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. Duffey, Dylan B. England, Zhigen Hu, Mitsuhiro Ito, Steven P. Langston, Charles McIntyre, Hirotake Mizutani, He Xu
  • Patent number: 9683003
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: June 20, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. Duffey, Dylan England, Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Publication number: 20170073326
    Abstract: The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: November 9, 2016
    Publication date: March 16, 2017
    Inventors: Indu T. BHARATHAN, Chris BLACKBURN, Jeffrey P. CIAVARRI, Jouhara CHOUITAR, Courtney A. CULLIS, Natalie D'AMORE, Paul E. FLEMING, Kenneth M. GIGSTAD, Krista E. GIPSON, Mario GIRARD, Yongbo HU, Janice LEE, Gang LI, Mansoureh REZAEI, Michael D. SINTCHAK, Francois SOUCY, Stephen G. STROUD, Tricia J. VOS, Tzu-Tshin WONG, He XU, Tianlin XU, Yingchun YE
  • Publication number: 20170002032
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Application
    Filed: June 30, 2015
    Publication date: January 5, 2017
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Matthew O. Duffey, Dylan England, Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Publication number: 20160381070
    Abstract: Embodiments of the present invention relate to identification of suspicious network traffic indicative of a Botnet and/or an Advanced Persistent Threat (APT) based on network protocol of such traffic. According to one embodiment, a traffic file is received at a network security device that is protecting a private network. The traffic file contains therein network traffic associated with the private network that has been captured and stored. The received traffic file is processed by the network security device to determine whether the network traffic relates to a network protocol that is indicative of existence of a network security threat within the private network. When existence of the network security threat is detected, then the network security device reports details regarding the network security threat.
    Type: Application
    Filed: June 26, 2015
    Publication date: December 29, 2016
    Applicant: FORTINET, INC.
    Inventors: Jie Zhang, He Xu
  • Publication number: 20160355504
    Abstract: Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra?, Rc, Rf, X2, Rd, Rd?, Re, Re?2, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.
    Type: Application
    Filed: July 1, 2014
    Publication date: December 8, 2016
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Matthew O. Duffey, Dylan B. England, Zhigen Hu, Mitsuhiro Ito, Steven P. Langston, Charles McIntyre, Hirotake Mizutani, He Xu
  • Publication number: 20160333007
    Abstract: The present invention provides a compound of formula I: wherein R1, X1, X2, R2, R3, R4, R5, n, and m are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: January 13, 2015
    Publication date: November 17, 2016
    Inventors: INDU T. BHARATHAN, Chris BLACKBURN, Jeffrey P. CIAVARRI, Jouhara CHOUITAR, Courtney A. CILLIS, Natalie D'AMORE, Paul E. FLE,OMG, Kenneth M. GIGSTAD, Kirsta E. GIPSON, Mario GIRARD, Yongbo HU, Janice LEE, Gang LI, Mansoureh REZAEI, Michael D. SINTCHAK, Francois SOUCY, Stephen g. STROUD, Tricia J. VOS, He XU, Yingchun YE
  • Patent number: 9382197
    Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: July 5, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, Sean J. Harrison, He Xu
  • Patent number: 9321731
    Abstract: This invention provides compounds of formula (I): wherein R1, R2, G, m, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: April 26, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Jeffrey P. Ciavarri, Kenneth M. Gigstad, He Xu
  • Publication number: 20160039789
    Abstract: This invention provides compounds of formula (I): wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Application
    Filed: May 28, 2014
    Publication date: February 11, 2016
    Inventors: Dylan B. England, He Xu, Kenneth M. Gigstad, Gould E. Alexandra, Ma Liting
  • Publication number: 20160031820
    Abstract: This invention provides compounds of formula (I): wherein R1, R2, G, m, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Application
    Filed: July 7, 2015
    Publication date: February 4, 2016
    Inventors: Christopher Blackburn, Jeffrey P. Ciavarri, Kenneth M. Gigstad, He Xu
  • Patent number: 9249142
    Abstract: This invention provides compounds of formula (I): wherein R1a, R1b, R1c, R1d, R2a, R2b, X1, X2, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 2, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, He Xu
  • Publication number: 20160009744
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Application
    Filed: June 30, 2015
    Publication date: January 14, 2016
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Matthew O. Duffey, Dylan England, Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Patent number: 9227951
    Abstract: This invention provides compounds of formula (I): wherein X1, X2, X3, R2, R4b, R1, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: January 5, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, He Xu
  • Publication number: 20150267165
    Abstract: The first method to cause a culture of human and other primate stem cells to directly and uniformly differentiate into a committed cell lineage is disclosed. Treatment of primate stem cells with a single protein trophoblast induction factor causes the cells to transform into human trophoblast cells, the precursor cells of the placenta. Several protein factors including bone morphogenic protein 4 (BMP4), BMP2, BMP7, and growth and differentiation factor 5 can serve as trophoblast-inducting factors.
    Type: Application
    Filed: June 2, 2008
    Publication date: September 24, 2015
    Inventors: Ren-He Xu, James A. Thomson